Nanoform’s CESS^® platform improves small-molecule formulations across the product lifecycle. CESS^® enables the production of crystalline and amorphous nanoparticles with precise control of particle size, morphology and polymorphic form, while avoiding the use of solvents and enabling high API loading. Case studies demonstrate the formulation impact of nanoforming across multiple compounds. In Phase I studies, nanoformed piroxicam tablets showed faster absorption and reduced pharmacokinetic variability compared with marketed formulations, while also enabling high drug loading and improved tabletability. For enzalutamide, nanocrystalline formulations achieved exposure comparable to amorphous solid dispersions with substantially higher drug load, supporting reduced pill burden through a single-tablet presentation. Additional examples highlight polymorph control, formulation stability and food-effect mitigation.